Company Sinovac Biotech Ltd.

SVA

AGP8696W1045

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2019-02-22 pm EST			5-day change	1st Jan Change
6.47 ^USD	-0.31%		-.--%	-.--%

Jan. 18	Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd.	CI
2023	Scientists see risk of lost opportunity for long COVID research in China	RE

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Number of employees: 3,558

Managers	Title	Age	Since
Wei Dong Yin CEO	Chief Executive Officer	60	03-08-31
Nan Wang DFI	Director of Finance/CFO	57	-
Qiang Gao COO	Chief Operating Officer	47	16-03-31
Helen G. Yang IRC	Investor Relations Contact	-	-
Guang Yang PRN	Corporate Officer/Principal	-	21-03-31
Coco Chang SAM	Sales & Marketing	-	-
Xiao Mei Yin SAM	Sales & Marketing	60	17-12-28

Members of the board	Title	Age	Since
Simon Anderson BRD	Director/Board Member	62	04-06-30
Wei Dong Yin CEO	Chief Executive Officer	60	03-08-31
Jian Li BRD	Director/Board Member	55	11-05-30
Yuk Lam Lo BRD	Director/Board Member	76	06-02-28
Meng Mei BRD	Director/Board Member	69	12-03-28
Shan Fu BRD	Director/Board Member	56	18-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	99,502,243	67,157,408 ( 67.49 %)	0	67.49 %
Stock B	0	14,630,813	0	0

Name	Equities	%	Valuation
Vivo Capital LLC 16.45 %	11,800,000	16.45 %	76 M $
SAIF Advisors Ltd. 15.03 %	10,780,820	15.03 %	70 M $
Wei Dong Yin 8.867 %	6,359,500	8.867 %	41 M $
CDH Investment Advisory Pte. Ltd. 8.365 %	6,000,000	8.365 %	39 M $
Prime Success LP 8.158 %	5,851,423	8.158 %	38 M $
1Globe Capital LLC 4.675 %	3,353,092	4.675 %	22 M $
OrbiMed Advisors Private Equity 3.791 %	2,718,735	3.791 %	18 M $
MW Gestion SA 0.0989 %	70,927	0.0989 %	458 898 $
The California Public Employees Retirement System 0.0958 %	68,732	0.0958 %	444 696 $
Navellier & Associates, Inc. 0.0190 %	13,641	0.0190 %	88 257 $

Sinovac Biotech Ltd.

No. 39 Shangdi Xi Road Haidan District

100085, Beijing

http://www.sinovac.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
SINOVAC BIOTECH LTD.	-.--%	642M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B